<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04720144</url>
  </required_header>
  <id_info>
    <org_study_id>2020-01719</org_study_id>
    <nct_id>NCT04720144</nct_id>
  </id_info>
  <brief_title>Breakthrough Invasive Mold Infections Under Posaconazole Prophylaxis (BIMI)</brief_title>
  <acronym>BIMI</acronym>
  <official_title>Multicenter Case-control Study of Breakthrough Invasive Mold Infections Under Posaconazole Prophylaxis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Vaudois</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Vaudois</source>
  <brief_summary>
    <textblock>
      Invasive mold infections (IMI) mainly affect patients with hematologic malignancies receiving&#xD;
      intensive chemotherapy or after hematopoietic stem cell transplantation (HSCT). Prolonged&#xD;
      neutropenia after remission induction chemotherapy (&gt;10 days duration) and continuous&#xD;
      immunosuppression in the context of prevention or therapy of graft versus host disease (GVHD)&#xD;
      for HSCT recipients (first 100 days post-transplantation and thereafter if GVHD is present)&#xD;
      are considered as periods at high risk of IMI.&#xD;
&#xD;
      Posaconazole prophylaxis is prescribed according to current guidelines to reduce the&#xD;
      occurrence of IMI. Nevertheless, breakthrough IMI (bIMI), i.e. IMI occurring under&#xD;
      mold-active prophylaxis, are still observed.&#xD;
&#xD;
      The investigators hypothesized that the epidemiology of bIMI (under posaconazole prophylaxis)&#xD;
      differs from that of IMI occurring in the absence of mold-active antifungal prophylaxis.&#xD;
      Because bIMI are rare events since the introduction of posaconazole prophylaxis,&#xD;
      epidemiological data of bIMI are scarce.&#xD;
&#xD;
      This study aims to i) describe the epidemiology, clinical features, treatment and outcome of&#xD;
      bIMI, ii) assess the causes of bIMI, iii) determine potential risk factors associated with&#xD;
      the developllement of bIMI iv) assess the impact of bIMI on overall mortality.&#xD;
&#xD;
      Design&#xD;
&#xD;
      Retrospective and prospective, observational, case-control, multicenter, international study.&#xD;
&#xD;
      The retrospective part will enroll previously identified bIMI cases and control cases (1:2)&#xD;
      over the last five years: October 1st 2015 to September 30st 2020.&#xD;
&#xD;
      The prospective part will enroll bIMI cases and control cases (1:2) occurring over a two-year&#xD;
      period: October 1st 2020 to September 30st 2022.&#xD;
&#xD;
      Setting&#xD;
&#xD;
      The aim is to enroll 10 to 15 European centers with dedicated units for hematologic cancer&#xD;
      patients. Currently, six centers have confirmed their participation (from Switzerland and&#xD;
      Germany).&#xD;
&#xD;
      Study Population&#xD;
&#xD;
      Adult (≥ 18 years old) patients with a hematologic malignancy receiving posaconazole&#xD;
      prophylaxis during induction, consolidation or re-induction chemotherapy or after HSCT.&#xD;
&#xD;
      Cases : patients receiving posaconazole prophylaxis for at least 7 days and diagnosed with&#xD;
      bIMI proven or probable according to EORTC-MSGERC.&#xD;
&#xD;
      Controls: patients receiving posaconazole prophylaxis for at least 7 days, without diagnosis&#xD;
      of bIMI possible, probable or proven according to EORTC-MSGERC.&#xD;
&#xD;
      The objective is to enroll about 100 bIMI cases and 200 controls.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Epidemiological description of bIMI</measure>
    <time_frame>At inclusion</time_frame>
    <description>Assessment of the cause of bIMI (intrinsically resistant mold pathogen vs susceptible mold pathogen but insufficient posaconazole serum concentration vs unknown)&#xD;
Description of clinical features, treatment and outcome of bIMI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of the risk factors of bIMI</measure>
    <time_frame>At inclusion</time_frame>
    <description>• Univariate and multivariate analyses of the parameters associated with an increased risk of bIMI (in particular, the association of a threshold of posaconazole concentration and bIMI) by comparison of bIMI cases with controls (posaconazole prophylaxis and no bIMI)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of the impact of bIMI on overall mortality</measure>
    <time_frame>6 weeks and 12 weeks after inclusion</time_frame>
    <description>• Comparison of mortality rate (6 and 12 weeks) between bIMI and control cases.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of factors influencing outcomes of bIMI</measure>
    <time_frame>6 weeks and 12 weeks after inclusion</time_frame>
    <description>• Univariate and multivariate analysis of predictors of mortality (6 and 12 weeks) among bIMI cases.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Invasive Mold Infections</condition>
  <condition>Breakthrough Invasive Mold Infections</condition>
  <condition>Hematologic Malignancy</condition>
  <condition>Hematologic Diseases</condition>
  <arm_group>
    <arm_group_label>bIMI cases</arm_group_label>
    <description>Adult (≥ 18 years old) patients with a hematologic malignancy receiving posaconazole prophylaxis (oral tablets or IV administration) for:&#xD;
i) Induction, consolidation or re-induction chemotherapy for acute leukemia or myelodysplastic syndrome (i.e. expected duration of neutropenia post-chemotherapy of ≥ 10 days) OR ii) Allogeneic hematopoietic stem cell transplant recipients during the post-transplantation phase (100-day post-transplantation) or later in case of intensified immunosuppression for moderate to severe graft vs host disease (GVHD).&#xD;
AND&#xD;
iii) Being diagnosed with proven or probable bIMI according to the EORTC-MSGERC classification (10) while on continuous posaconazole prophylaxis for at least 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>For each bIMI case, we will include 2 control cases fulfilling the following criteria:&#xD;
i) Receiving continuous posaconazole prophylaxis for at least 7 days&#xD;
ii) No diagnosis of proven, probable or possible IMI according to EORTC-MSGERC classification (10) during the entire hospital stay</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Adults diagnosed with hematologic malignancies under posaconazole prophylaxis for one of&#xD;
        the above mentionned reasons.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Cases:&#xD;
&#xD;
        Adult (≥ 18 years old) patients with a hematologic malignancy receiving posaconazole&#xD;
        prophylaxis (oral tablets or IV administration) for:&#xD;
&#xD;
        i) Induction, consolidation or re-induction chemotherapy for acute leukemia or&#xD;
        myelodysplastic syndrome (i.e. expected duration of neutropenia post-chemotherapy of ≥ 10&#xD;
        days)&#xD;
&#xD;
        OR&#xD;
&#xD;
        ii) Allogeneic hematopoietic stem cell transplant recipients during the&#xD;
        post-transplantation phase (100-day post-transplantation) or later in case of intensified&#xD;
        immunosuppression for moderate to severe graft vs host disease (GVHD).&#xD;
&#xD;
        AND&#xD;
&#xD;
        iii) Being diagnosed with proven or probable bIMI according to the EORTC-MSG classification&#xD;
        (10) while on continuous posaconazole prophylaxis for at least 7 days.&#xD;
&#xD;
          -  Controls:&#xD;
&#xD;
        For each bIMI case, we will include 2 control cases fulfilling the following criteria:&#xD;
&#xD;
        i) Receiving continuous posaconazole prophylaxis for at least 7 days&#xD;
&#xD;
        ii) No diagnosis of proven, probable or possible IMI according to EORTC-MSG classification&#xD;
        (10) during the entire hospital stay.&#xD;
&#xD;
        And matched to bIMI cases according to the following criteria:&#xD;
&#xD;
        iii) Hospitalization in the same ward within the same year (+/- 12 months interval)&#xD;
&#xD;
        iv) Same underlying condition related to hematologc cancer: a) HSCT within 100 days&#xD;
        post-engraftment, b) HSCT &gt; 100 days post-engraftment with intensified immunosuppressive&#xD;
        regimen for severe GVHD, c) induction chemotherapy for acute myeloid or lymphoid leukemia,&#xD;
        or myelodysplastic syndrome, d) other hematologic disorders (e.g. aplastic anemia) with&#xD;
        prolonged neutropenia and/or immunosuppressive regimen.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a diagnosis of possible IMI according to the EORTC-MSG classification.&#xD;
&#xD;
          -  Patients with a positive fungal biomarker in serum (e.g. galactomannan or beta-glucan)&#xD;
             in the absence of clinical or radiological criteria of IMI according to the EORTC-MSG&#xD;
             classification.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frederic Lamoth</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire Vaudois</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Frederic Lamoth</last_name>
    <phone>+41213141111</phone>
    <email>frederic.lamoth@chuv.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical University of Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cornelia Lass-Flörl</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Cologne</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jannick Stemler</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Basel</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nina Khanna</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Zimmerli</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Cantonal de Fribourg</name>
      <address>
        <city>Fribourg</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Véronique Erard</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Genève (HUG)</name>
      <address>
        <city>Geneva</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dionysios Neofytos</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois (CHUV)</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frederic Lamoth</last_name>
      <phone>+41213141111</phone>
      <email>frederic.lamoth@chuv.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St.Gallen</name>
      <address>
        <city>Saint Gallen</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kattia Boggian</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 19, 2021</study_first_submitted>
  <study_first_submitted_qc>January 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2021</study_first_posted>
  <last_update_submitted>February 5, 2021</last_update_submitted>
  <last_update_submitted_qc>February 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Universitaire Vaudois</investigator_affiliation>
    <investigator_full_name>Frederic Lamoth</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Posaconazole</keyword>
  <keyword>Antifungal prophylaxis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Hematologic Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

